Real life cases | Elise Smolders

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Specific Complex Interactions (mechanic presentation) | David Burger, PharmD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Backing up clinical data with modelling | Marco Siccardi, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Back-terial co-infections | Mohammed Lamorde, FRCP, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

The ‘Back Side’ of Compartments | Saye Khoo, MD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Will we see the Back of DDIs? | Catia Marzolini, PharmD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Pharmacogenetics - Back to reality | Andrew Owen, BSS, MSC, PhD, FSB

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Looking Backwards: Hormonal Contraception and ART | Kimberly Scarsi, PharmD, MS, FCCP

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Janssen - Rilpivirine | Herta Crauwels, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Target Concentrations | Angela Kashuba, PharmD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

The FDA Perspective on Hepatitis C Drug Resistance | Patrick Harrington, PHD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika | Steven Kern, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Long acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSB

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Lost in translation: learning from preclinical data | Gerry Davies

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

A new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Pharmacokinetic Modeling and Simulation of the Interaction between Moxifloxacin and Rifapentine in Healthy Volunteers | M. Imperial

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Lung Tissue Concentrations of Pyrazinamide among Patients with Tuberculosis | R. Kempker

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Early interventions for diabetes related tuberculosis hasten sputum microbiological clearance in Virginia, USA | S. Heysell

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Sub-therapeutic concentrations of anti-tuberculosis drugs in children when treated according to indian dosing recommendation | B. Guiastrennec

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

A Need for altering Tuberculosis Dosing Regiments for patients with HIV-associated Tuberculous Meningitis | G. Aljayyoussi

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016